omeprazole sulfone has been researched along with ici 204,219 in 1 studies
Studies (omeprazole sulfone) | Trials (omeprazole sulfone) | Recent Studies (post-2010) (omeprazole sulfone) | Studies (ici 204,219) | Trials (ici 204,219) | Recent Studies (post-2010) (ici 204,219) |
---|---|---|---|---|---|
50 | 12 | 17 | 463 | 101 | 91 |
Protein | Taxonomy | omeprazole sulfone (IC50) | ici 204,219 (IC50) |
---|---|---|---|
Solute carrier family 22 member 2 | Homo sapiens (human) | 9.7 | |
Epidermal growth factor receptor | Homo sapiens (human) | 5.751 | |
Adenosine receptor A3 | Homo sapiens (human) | 1.363 | |
Cytochrome P450 2C9 | Homo sapiens (human) | 2.2575 | |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 1.363 | |
Thromboxane-A synthase | Homo sapiens (human) | 3.81 | |
Mitogen-activated protein kinase 3 | Homo sapiens (human) | 4.376 | |
Mitogen-activated protein kinase 1 | Homo sapiens (human) | 0.538 | |
Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | 2 | |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 1.363 | |
Sodium/bile acid cotransporter | Homo sapiens (human) | 6.5 | |
Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.353 | |
Cysteinyl leukotriene receptor 1 | Cavia porcellus (domestic guinea pig) | 0.002 | |
Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 7.6 | |
Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.3 | |
Cysteinyl leukotriene receptor 2 | Homo sapiens (human) | 7.397 | |
Cysteinyl leukotriene receptor 1 | Homo sapiens (human) | 0.0039 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afzelius, L; Andersson, TB; Baroni, M; Cruciani, G; Karlén, A; Masimirembwa, CM; Mecucci, S; Zamora, I | 1 |
1 other study(ies) available for omeprazole sulfone and ici 204,219
Article | Year |
---|---|
Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.
Topics: Amino Acids; Aryl Hydrocarbon Hydroxylases; Binding Sites; Cytochrome P-450 CYP2C9; Enzyme Inhibitors; Models, Molecular; Molecular Conformation; Molecular Structure; Quantitative Structure-Activity Relationship | 2004 |